Abstract: The binder comprises two faces, a back and two flaps respectively extending from a face and adapted to be folded to close the binder, an external envelope of transparent plastic material, a ring mechanism fixed inside the back, and a magnetic closure arranged on the flaps, this magnetic closure being constituted by a magnet positioned in a housing of the plastic envelope defining a flap, and a metallic plate positioned in a housing of the envelope defining the second flap with the plate and the first magnet having identical dimensions and are placed so that their perimeters coincide to be applied one against the other.

Abstract: The binder comprises two faces, a back and two flaps respectively extending a face and adapted to be folded to close the binder, an external envelope of plastic material, a ring mechanism fixed inside the back, and a magnetic closure arranged on the flaps, this magnetic closure being constituted by a magnet positioned in a housing of the plastic envelope defining a flap, and a metallic plate positioned in a housing of the envelope defining the second flap. The plate and the magnet have identical dimensions and a placed so that their perimeters coincide to be applied one against the other.

Abstract: Compounds of formula (I): ##STR1## wherein: R.sub.1 represents an unsubstituted or substituted alkyl,R.sub.2 represents an unsubstituted or substituted alkyl,A represents, with the nitrogen and carbon atoms to which it is attached, a nitrogenous mono- or polycyclic structure, andB represent any one of the radicals a through j as defined in the description, and medicaments containing the same, are useful as human leucocyte elastase inhibitors.

Abstract: Compound of formula (I): ##STR1## in which: R.sub.1 represents 1-adamantyl, dicyclopropylmethyl, substituted or unsubstituted (C.sub.3 -C.sub.6) cycloalkyl or substituted or unsubstituted bicyclo[2.2.2]oct-1-yl,R.sub.2 represents: ##STR2## in which: m represents 1, 2 or 3,X represents oxygen or sulfur or N--R,R.sub.3 or R.sub.4, which are identical or different, represent hydrogen, (C.sub.1 -C.sub.6) alkyl or trifluoromethyl, ##STR3## n represents 0, 1 or 2, R.sub.5 represents hydroxy, or (C.sub.1 -C.sub.6) alkoxy, and anti-inflammatory medicinal products containing the same.

Abstract: Compound of formula (I): ##STR1## in which: R.sub.1 represents halogen, or hydroxy, alkyl, alkoxy, cyano, amino, mercapto, alkylthio or phenoxy,R.sub.2 and R'.sub.2 represent two hydrogen when the ring is unsaturated, or alternatively identical or different, represent hydrogen or halogen, or hydroxy, alkyl, alkoxy, cyano, amino or oxo when the ring is saturated,R.sub.3 represents any one of the following groups: ##STR2## in which: m represents 1, 2 or 3,X represents oxygen or sulfur or N-R, R.sub.5 or R.sub.6, which are identical or different, represent hydrogen or alkyl or trifluoromethyl or form (C.sub.3 -C.sub.6) cycloalkyl,n represents 0, 1 or 2,R.sub.7 represents hydroxy, alkoxy, amino, or --O--CH.sub.2 --CO--NRR',R.sub.4 represents hydrogen or halogen or alkyl, alkoxy or trihaloalkyl.

Abstract: The invention relates to the compounds of formula (I): ##STR1## in which: A represents, with the nitrogen and carbon atoms to which it is bound, a heterocycle,B represents, with the nitrogen atom to which it is bound, a heterocycle,R.sub.1 represents alkoxy, benzyloxy, phenoxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted cycloalkyl,their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid, medicinal products containing the same.

Abstract: The present invention relates to a valve including a valve member co-operating with a seat provided with a crenellated portion disposed around the portion of the seat on which the valve member rests, said crenellated portion being constituted by teeth separated by gaps, the inside walls of the teeth being portions of a vertical axis cylinder, the width l of the gaps being less than the width b of the inside walls of the teeth, wherein the end wall of the valve member facing the crenellated portion when the valve member is in its closed position is convex in shape, co-operating with the inside wall of each tooth to form a channel that flares from top to bottom of the tooth, the point of contact C between the valve member and the seat being at a distance d from the base B of the crenellated portion lying in the range 0.25 times to 0.5 times the width l of the gap. Vibrations are eliminated at partial load and pressure fluctuations downstream from the valve are reduced.

Abstract: Fibre-reinforced tubes made of a thermoplastics material are manufactured using a method of extruding thermoplastics material in a drawplate with a diverging end zone, the end zone of which has a diverging annular flow space which has a ratio A.sub.s /A.sub.e between the exit area and entry area of at least 1.2, and a ratio between the length 1 of the lower edge of the annular exit space of the diverging zone and the width e of the straight section of said annular space which is less than 5; the extrusion operation being carried out in the presence of a liquid lubricant which is incompatible with said thermoplastics material at extrusion temperatures, said lubricant being present at the level of the external wall and at the level of the internal wall of said flow space. Tubes which are manufactured by way of this method are particularly resistant to a high degree of bursting and have an improved surface quality.

Abstract: The invention relates to the compounds of formula (I): ##STR1## in which: A represents, with the nitrogen and carbon atoms to which it is bound, a heterocycle,B represents, with the nitrogen atom to which it is bound, a heterocycle,R.sub.1 represents alkoxy, benzyloxy, phenoxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted cycloalkyl,their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid, medicinal products containing the same.

Abstract: The invention relates to a compound of formula (I): ##STR1## which can be used as N-myristoyltransferase inhibitors, in which R.sub.1 represents hydrogen, substituted or unsubstituted (C.sub.1 -C.sub.6) alkyl, substituted or unsubstituted phenyl, (C.sub.3 -C.sub.7) cycloalkyl methyl, substituted or unsubstituted (imidazolyl-2-yl)methyl, substituted or unsubstituted (indol-3-yl)methyl or (1-azaindolizin-2-yl)methyl,R.sub.2, R.sub.3, which are identical or different, represent hydrogen or (Cl-C6) alkyl,or when R.sub.1 represents hydrogen, R.sub.2 and R.sub.3 form with the carbon and nitrogen atoms to which they are attached, a mono-, bi- or tricyclic heterocycle,X represents --CO--, --SO.sub.2 --, --PO(OH)--,Y represents --COR.sub.5 or --POR.sub.6 R.sub.6 ',R.sub.4 represents substituted or unsubstituted, linear or branched (C.sub.6 -C.sub.

Abstract: A blade array for turbomachines comprises blades disposed between an inner wall and an outer wall. The inner wall and/or the outer wall is provided with a suction port near at least some blades. This port has a first end situated along the upper surface in a region of the blade extending from the point of maximum curvature to the neck of the passage between said blade and the adjacent blade. The port enabling the efficiency to be increased is oriented along an isobar line. Its length is such that the second end is spaced from the upper surface of the blade by a distance between one quarter and one half the width of the neck of the inter-blade passage.

Abstract: The invention relates to compounds of formula (I): ##STR1## in which: A represents, with the carbon and nitrogen atoms to which it is linked, cyclic amide as defined in the description,B represents, with the nitrogen and carbon atoms to which it is linked, saturated polycyclic structure as defined in the description,R represents hydrogen, optionally substituted lower alkyl, optionally substituted (4-imidazolyl)methyl, (3-pyrazolyl)methyl or optionally substituted (2-pyridyl)methyl,their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid.Medicinal products.

Abstract: The invention relates to the use of N-myristoyl-(S)-phenylalanine in the treatment of diseases involving myristoylation such as cancer or AIDS.Medicinal products including N-myristoyl-(S)-phenylalanine which are effective for such purpose.

Abstract: The invention relates to the compounds of formula (I): ##STR1## in which: R.sub.1 represents a linear or branched, lower or higher alkoxy group or a substituted or unsubstituted amino group,R.sub.2 represents a lower alkyl group unsubstituted or substituted with an amino group,R.sub.3 represents an amino, lower or higher alkoxy or a hydroxyl group, with the proviso, however, that at least one amino group is present in R.sub.1 or R.sub.3,R.sub.4 represents a hydrogen atom or an aryl group,m is equal to 1 or 2,n is between 1 and 6, andRa and Rb, which may be identical or different, represent a hydrogen atom when m=1, or a hydrogen atom or an alkyl group when m=2 andmedicinal products.

Abstract: A valve comprises a valve obturator cooperating with a valve seat provided with crenellations disposed around the part of the valve seat on which the valve obturator rests. Each crenellation comprises on its surface facing the valve obturator a vertical central partition between two symmetrical openings.

Abstract: The invention relates to the compounds of general formula (I): ##STR1## in which: A represents, with the carbon and nitrogen atoms to which it is linked, a cycloamide group,B represents, with the carbon and nitrogen atoms to which it is linked, a saturated polycyclic structure,R represents a hydrogen atom, alower alkyl group or a substituted or unsubstituted 4-imidazolylmethyl group,their diastereoisomers, enantiomers and epimers, as well as their addition salts with a pharmaceutically acceptable acid.Medicinal products.

Abstract: The invention relates to the compounds of general formula: ##STR1## in which: X denotes either an oxygen atom, or two hydrogen atoms;Y denotes either a hydrogen atom, or a hydroxyl group;or Y denotes an amino group on condition that X denotes two hydrogen atoms;R denotes a hydrogen atom, or a straight- or branched-chain alkyl group having 1 to 6 carbon atoms, optionally substituted with one or more hydroxy, amino, mercapto, methylthio or carboxy groups, or aryl groups such as phenyl, pyridyl or thienyl; ##STR2## denotes a polycyclic nitrogenous structure; their enantiomers, epimers and diastereoisomers, as well as their addition salts with a pharmaceutically acceptable acid or base.

Abstract: Tetrapeptide compounds of general formula: ##STR1## in which R denotes:a hydrogen atom,a straight- or branched-chain alkyl radical containing from 1 to 4 carbon atoms,an aryl radical such as phenyl or a heterocyclic aromatic radical such as thienyl, optionally substituted with a hydroxy, amino, mercapto, methylthio or lower alkyl group,a lower aralkyl radical such as benzyl,R' denotes a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms,X denotes an oxygen atom or an NH group,Y denotes an oxygen or sulfur atom when X denotes an NH group, or Y denotes an NH group when X denotes an oxygen atom,t denotes 0 or 1, ##STR2## denotes a nitrogen-containing polycyclic structure, their enantiomers, epimers and diastereoisomers, as well as their addition salts with a pharmaceutically acceptable acid or base.Medicinal products.

Abstract: Compounds of formula (I): ##STR1## in which E denotes a lower alkyl group, or preferably a hydrogen atom, and their addition salts with a pharmaceutically acceptable acid or base, the preparation thereof and pharmaceutical compositions containing them.

Abstract: Process for the industrial synthesis of (2S,3 7aS)-2-carboxyperhydroindole by reduction of 2-carboxindole or of one of its esters to (R,S)-2-carboxyindo or of one of its esters which, after saponification, converted into the acid, the S isomer cf (R,S)-2-carboxyindoline being obtained by precipitation from the mixture of the two (R) and (S) isomers, in the presence of (+) methylbenzylamine, (S)-2-carboxyindoline being in its turn subjected to catalytic hydrogenation to give (2S, 3aS,7aS)-2-carboxyperhydroindole, after separation of (2S,3aR,7aR) isomer by crystallization.Application to the synthesis of carboxyalkyl d peptides capable of being employed in therapeutics.